67 completed, 9 terminated, 7 active not recruiting, 4 recruiting. 97 Phase 3, 24 Phase 2.
Follow Duke University: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST) Liposomal Amphotericin B (LAmB), Flucytosine (5FC), Flucytosine (5FC) placebo pill - Talaromycosis | Phase 3 | Not yet recruiting | Duke University | 428 | 2026-11-01 | 2026-09-21 |
| PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis Rosuvastatin 20 Mg Oral Tablet, Colchicine 0.5 MG Oral Tablet Once Daily, Placebo - Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression | Phase 3 | Recruiting | Duke University | 1500 | 2026-07-21 | 2026-10-07 |
| Phenobarbital for Agitated Delirium Phenobarbital, Conventional therapy group - Agitated Delirium, Delirium Confusional State | Phase 3 | Not yet recruiting | Duke University | 150 | 2026-06-01 | 2026-04-23 |
| Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab - Polyarticular Course Juvenile Idiopathic Arthritis (JIA) | Phase 3 | Recruiting | Duke University | 400 | 2026-01-09 | 2026-10-21 |
| Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology Hyperpolarized xenon 129, Cardiopulmonary Stress Test, Pulmonary Function Test - Electronic Cigarette Related Lung Damage | Phase 2 / Phase 3 | Recruiting | Y. Michael Shim, MD | 80 | 2024-12-19 | 2026-03-17 |
| Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration OTX-TKI, Aflibercept - Neovascular Age-related Macular Degeneration | Phase 3 | Active not recruiting | Ocular Therapeutix, Inc. | 825 | 2024-11-27 | 2025-06-17 |
| Lemborexant Treatment of Insomnia Linked to Epilepsy Lemborexant, Placebo - Epilepsy, Sleep | Phase 3 | Recruiting | University of Manitoba | 26 | 2024-10-29 | 2025-02-13 |
| Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp Elagolix 200 MG, Placebo or SOC IVF - Infertility, Endometriosis | Phase 3 | Active not recruiting | Yale University | 97 | 2024-03-16 | 2026-06-05 |
| Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration OTX-TKI (axitinib implant), Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 3 | Active not recruiting | Ocular Therapeutix, Inc. | 344 | 2024-01-29 | 2025-04-18 |
| Oral N-acetylcysteine for Retinitis Pigmentosa N-acetylcysteine, Placebo - Retinitis Pigmentosa | Phase 3 | Active not recruiting | Johns Hopkins University | 485 | 2023-10-11 | 2026-06-15 |
| Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia Online Pain Coping Skills Training, Education - Breast Cancer, Arthralgia | Phase 3 | Active not recruiting | Northwestern University | 452 | 2023-01-19 | 2026-07-08 |
| Nonpharmacologic Pain Management in FQHC Primary Care Clinics Brief Pain Teleconsult, Telehealth Physical Therapy - Low Back Pain, Chronic Pain | Phase 3 | Active not recruiting | University of Utah | 500 | 2021-11-04 | 2026-04-07 |
| PREFERENTIAL Study Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE] - Cataract Surgery, Glaucoma Surgery | Phase 2 / Phase 3 | Withdrawn | Duke University | 2020-11-01 | 2021-11-17 | |
| Sling vs Botox for Mixed Incontinence Botox® injection, Mid-urethral sling - Urinary Incontinence, Stress, Urinary Incontinence, Urge | Phase 3 | Completed | NICHD Pelvic Floor Disorders Network | 150 | 2020-06-08 | 2025-06-03 |
| Antibiotic Prophylaxis in Rhinoplasty Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg., Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days - Nasal Obstruction, Nasal Surgical Procedures | Phase 3 | Enrolling by invitation | Stanford University | 864 | 2020-05-20 | 2026-04-24 |
| Strengthening Referral Networks for Management of Hypertension Across the Health System (STRENGTHS) Health IT and Peer Support Intervention - Hypertension | Phase 3 | Unknown | Moi University | 1600 | 2020-01-17 | 2023-03-16 |
| Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) Abatacept Injection, Usual Care - Juvenile Idiopathic Arthritis | Phase 3 | Completed | Duke University | 121 | 2019-10-29 | 2026-01-23 |
| Comparing Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease Patient-Specific Protocol, Weight-based Protocol, Morphine - Sickle Cell Disease | Phase 3 | Terminated | Duke University | 328 | 2019-08-13 | 2023-07-03 |
| Minimize Menorrhagia in Women With Von Willebrand Disease recombinant von Willebrand factor, tranexamic acid - Von Willebrand Diseases | Phase 3 | Terminated | Margaret Ragni | 39 | 2019-02-07 | 2024-07-01 |
| Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain Supported-Self Management (SSM), Spinal Manipulation Therapy (SMT), SMT + SSM - Acute Pain, Low Back Pain, Mechanical | Phase 3 | Completed | University of Minnesota | 1000 | 2018-11-01 | 2025-10-16 |
Showing 20 of 97. Sign in to see all of them.
Heart Failure (10) · Depression (6) · Anxiety Disorders (5) · Cigarette Smoking (4) · Tobacco Use Disorder (4) · Cardiovascular Diseases (3) · Depressive Disorder, Major (3) · Heart Diseases (3) · Idiopathic Pulmonary Fibrosis (3) · Motor Activity (3) · Myocardial Infarction (3) · Smoking Cessation (3) · Stress Disorders, Post-Traumatic (3) · Urinary Incontinence, Stress (3) · Urinary Incontinence, Urge (3)
Sertraline (7) · Tobacco Use Cessation Devices (5) · Bupropion (4) · Varenicline (4) · Cognitive Behavioral Therapy (3) · Escitalopram (3) · Abatacept (2) · Acetylcysteine (2) · Botulinum Toxins, Type A (2) · Calcium Dobesilate (2) · Colchicine (2) · Dexmedetomidine (2) · Hydromorphone (2) · Levetiracetam (2) · Modafinil (2)
United States (83) · Canada (8) · Argentina (2) · Australia (2) · Germany (2) · Netherlands (2) · Puerto Rico (2) · Singapore (2) · Austria (1) · Egypt (1) · France (1) · India (1) · Italy (1) · Kazakhstan (1) · Kenya (1)
Jonathan Davidson, M.D. (5) · Ashwin A Patkar, MD (4) · Jed E Rose, Ph.D. (4) · Kerry L. Lee, PhD (4) · Eugene Braunwald, MD (3) · Fernando Martinez, MD (3) · Ganesh Raghu, MD (3) · Imre Noth, MD (3) · James Loyd, MD (3) · Jay Ryu, MD (3) · Jesse Roman, MD (3) · Joe Lasky, MD (3) · Kevin Anstrom, PhD (3) · Kevin Brown, MD (3) · Rob Kaner, MD (3)
PMID 25890798, PMID 26111071, PMID 18477783, PMID 25543972, PMID 26041600, PMID 26927285, PMID 35224730, PMID 35688625, PMID 37142273, PMID 15577756, PMID 16537663, PMID 17846259, PMID 17904460, PMID 17996052, PMID 18348595, PMID 18615172, PMID 18760123, PMID 19183470, PMID 19329820, PMID 19351941, PMID 19351942, PMID 19376309, PMID 19458364, PMID 19755366, PMID 19782784, PMID 19782785, PMID 19782786, PMID 19782787, PMID 19782789, PMID 19782791, PMID 19782792, PMID 19825809, PMID 20101071, PMID 20124123, PMID 20379614, PMID 20484178, PMID 20547904, PMID 20551371, PMID 20670760, PMID 20670761, PMID 20716738, PMID 20723799, PMID 20811658, PMID 20825316, PMID 21148807, PMID 21331567, PMID 21366472, PMID 21463150, PMID 21463153, PMID 21612471
U01HL084904 (4), U01HD069031 (3), U10HL080413 (3), P50DA027840 (2), U01DK058982 (2), U10HD041261 (2), U10HD041267 (2), U10HD054214 (2), U10HD054215 (2), U10HD069010 (2), U10HD069013 (2), U10HD069025 (2), 1UG1EY033293 (1), R01AR052368 (1), R01HL080664 (1)